peptides for stress · Semax · Selank · BDNF · enkephalin · research use only
Peptides for Stress: Semax, Selank, and the Research Behind Them
'Stress' and 'anxiety' overlap in clinical language but refer to distinct biological processes worth separating when looking at peptide research. Anxiety is primarily an amygdala-mediated fear and worry response. Stress in the physiological sense refers to HPA-axis activation, cortisol output, and the downstream effects of chronic glucocorticoid exposure — including BDNF depletion, reduced hippocampal neurogenesis, and dopaminergic dysregulation. The two research peptides most studied in these contexts are Semax (an ACTH(4-7)PGP analog that acts through BDNF/NGF induction and dopaminergic augmentation) and Selank (a tuftsin analog that inhibits enkephalinase and modulates GABA-A tone). This page is general educational context about research compounds. Titan Peptide Lab supplies both as nasal sprays for laboratory and research use only — not for human use, not as adaptogens or stress supplements, not as medical advice.
Semax: the BDNF angle on chronic stress
Chronic stress reliably depletes BDNF (brain-derived neurotrophic factor) — this is one of the best-replicated findings in stress neuroscience. Lower BDNF correlates with reduced hippocampal volume, impaired learning, and mood dysregulation. Semax is an ACTH(4-7) fragment with a C-terminal Pro-Gly-Pro extension that dramatically upregulates BDNF and NGF expression. Dolotov et al. 2006 (PMID 16996037) showed hippocampal BDNF mRNA increased approximately 1.4× and trkB mRNA 1.6× in rodents given Semax; exon-III BDNF mRNA (the neuronally-active promoter) increased approximately 3×. Agapova et al. 2008 (PMID 18756821) tracked the gene-expression dynamics: BDNF and NGF genes activate within 20–90 minutes of Semax administration. This BDNF-upregulation mechanism is directly relevant to stress models because it works in the same molecular direction that stress depletes.
Semax research dosing reference →Semax and the cortisol question
Semax is an ACTH analog — which might suggest it stimulates cortisol. It does not. The full ACTH molecule stimulates the MC2R receptor on adrenal cortex cells to produce cortisol, but MC2R requires the full ACTH sequence. Semax's active core is ACTH(4-7)PGP, which lacks the MC2R-binding region. In the published human EEG study, Kaplan et al. 1996 (Neurosci Res Commun 19(2):115-123) showed Semax improved sustained-attention performance and work efficiency in operators under task load — without the cortisol-mediated arousal or adrenal side effects of full ACTH agonists. Eremin et al. 2005 (Neurochem Res 30:1493-1500) documented dopaminergic augmentation without steroid-axis effects. This selective ACTH-fragment profile is what distinguishes Semax from the broader peptide category: it accesses downstream cognitive/neuroprotective effects of the ACTH pathway while bypassing the cortisol-stimulating arm.
Semax tolerability data →Selank: enkephalins and the stress-tonicity connection
Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) inhibits enkephalinase (neutral endopeptidase 24.11 / neprilysin) with an IC50 of approximately 15 µM (Zozulya 2001, PMID 11550013). Enkephalinase degrades endogenous opioid peptides — met-enkephalin, leu-enkephalin, dynorphin — which modulate the stress response at limbic and brainstem levels. By inhibiting this enzyme, Selank prolongs the activity of the body's endogenous enkephalin tone, reducing the sympathetic and HPA-axis amplification that drives acute stress into a chronic physiological state. This is mechanistically distinct from benzodiazepine sedation (GABA-A positive allosteric modulation) and from SSRI serotonin reuptake inhibition. The Selank-enkephalin axis maps more naturally to the 'edge off acute stress' concept than to clinical-grade anxiolytic sedation.
Selank research dosing reference →The complementary mechanism: Semax + Selank together
Semax and Selank address the stress picture from different angles, which is why they are often studied as a pair. Semax acts primarily at the top of the HPA-axis cascade — BDNF/NGF induction, dopaminergic tone, sustained-attention maintenance under load (Kaplan 1996). Selank acts at the periphery of the endogenous opioid/stress circuit — enkephalinase inhibition, GABA-A modulation, anxiolytic tone without sedation. In the one head-to-head study (Zozulya 2008, PMID 18454096), Selank combined antiasthenic (anti-fatigue, Semax-like) and anxiolytic properties — suggesting some mechanism overlap. Titan's Selank+Semax Stack at $105 was designed around this pairing. The research framing: Semax targets chronic-stress depletion of BDNF/dopamine; Selank targets acute-stress amplification via enkephalin tone.
Semax vs Selank: full comparison →What the human data actually shows
Most of the BPC mechanism data above is rodent. The human evidence is specifically: Kaplan 1996 — a small Russian EEG study in healthy operators under cognitive load showing improved sustained attention after Semax nasal administration. Zozulya 2008 — an n=62 controlled trial in GAD/neurasthenia patients comparing Selank to medazepam. Neither study was conducted under modern ICH-GCP trial design standards, and neither was primarily a 'stress' study (Kaplan was cognitive performance, Zozulya was clinical anxiety disorder). There is no Western-registered RCT measuring Semax or Selank on validated HPA-axis or cortisol endpoints in healthy humans under a standardised stress protocol. That gap is real and worth stating plainly.
Selank anxiety research overview →What adaptogens, Semax, and Selank do not do
Neither Semax nor Selank is a cortisol blocker. Neither suppresses the HPA axis. Neither replaces sleep, removes the stressor, or recalibrates a genuinely dysregulated cortisol system. The research framing is: BDNF upregulation under Semax may buffer some downstream effects of cortisol-depleted neuroplasticity; Selank's enkephalinase inhibition may reduce acute amplification of the stress response. Neither compound is marketed or approved for stress or any other clinical application. Both are research-use-only materials. This is not a treatment page — it is a map of what the published preclinical and limited human literature has studied.
Nootropic nasal peptides overview →Mechanism comparison
Semax vs Selank: stress-relevant pathways, targets, and evidence quality.
A plain comparison of the two compounds on the dimensions most relevant to stress research. Both supplied as RUO nasal sprays by Titan.
- Primary target
- Semax: BDNF/NGF gene expression (via MC3R/MC4R-adjacent signalling) + dopaminergic augmentation. Selank: enkephalinase (neutral endopeptidase 24.11) inhibition → prolonged endogenous opioid tone.
- Does it affect cortisol?
- Semax: No. Lacks MC2R-binding ACTH region; no adrenocortical steroid effect documented. Selank: Not directly; modulates downstream stress amplification without HPA-axis stimulation.
- Best human evidence
- Semax: Kaplan 1996 (EEG, sustained attention, healthy operators). Selank: Zozulya 2008 (PMID 18454096, n=62, vs medazepam, GAD/neurasthenia).
- Stress vs anxiety framing
- Semax maps better to chronic-stress depletion (BDNF deficits, cognitive load, dopamine under sustained task). Selank maps better to acute-stress amplification (enkephalin tone, GABA-A modulation, anxiolytic-without-sedation profile).
- Evidence quality
- Both have limited, Russia-only human data. Neither has a Western ICH-GCP RCT on HPA-axis or validated stress endpoints. Mechanism is preclinical. Honest tier: Tier 2 (mixed human + preclinical) for Selank anxiety; Tier 2 for Semax cognitive; Tier 3 for stress-specific endpoints.
Questions researchers ask
Before you order.
- What peptides are studied for stress?
- The two research peptides with the most stress-adjacent published evidence are Semax (ACTH fragment that upregulates BDNF/NGF and augments dopaminergic tone without stimulating cortisol) and Selank (tuftsin analog that inhibits enkephalinase, prolonging endogenous opioid/enkephalin tone and reducing acute stress amplification). Both have limited human data from Russian trials. Neither is approved for stress treatment.
- Does Semax lower cortisol?
- No. Semax is an ACTH(4-7) fragment that lacks the MC2R-binding region required to stimulate adrenocortical cortisol production. It does not suppress cortisol either. Its stress-relevant effects are downstream: BDNF upregulation and dopaminergic augmentation, which may buffer some cognitive consequences of chronic cortisol exposure but do not directly modulate the HPA axis.
- How is peptide stress research different from adaptogens?
- Most adaptogenic herbs (ashwagandha, rhodiola, etc.) are proposed to modulate the HPA axis directly — typically reducing cortisol output. Semax and Selank work differently: Semax acts on BDNF/dopamine pathways downstream of HPA activation; Selank acts on endogenous opioid tone in the stress circuitry. Neither is a classic adaptogen, and neither directly blocks cortisol synthesis or release.
- Can I use Semax or Selank for stress?
- Titan supplies Semax and Selank as RUO laboratory materials — not for personal use, not for stress management, and not as supplements or treatments of any kind. If you are experiencing stress-related symptoms, work with a licensed healthcare provider. This page is a reference for researchers who want to understand what the published literature has studied.